Abstract
The recent successful clinical translation of nuclear theranostics ([1][1],[2][2]) fueled industry investment in the radiopharmaceutical market ([3][3]). Among other examples, Novartis invested $6 billion to acquire Endocyte (177Lu-PSMA-617) and Advanced Accelerator Applications (AAA; 177Lu-DOTATATE
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have